Education
About Us
Working with TipRanks
Follow Us
TransMedics Group Inc (TMDX)
NASDAQ:TMDX
TMDX Stock Chart & Stats
$142.71
-$4.08(-5.19%)
At close: 4:00 PM EST
$142.71
-$4.08(-5.19%)
Day’s Range― - ―
52-Week Range$55.00 - $156.00
Previous CloseN/A
Volume1.17M
Average Volume (3M)636.20K
Market Cap
$4.60B
Enterprise Value$3.88B
Total Cash (Recent Filing)$466.17M
Total Debt (Recent Filing)$519.35M
Price to Earnings (P/E)57.6
Beta1.06
Next Earnings
Mar 04, 2026EPS Estimate
0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.66
Shares Outstanding34,174,324
10 Day Avg. Volume477,417
30 Day Avg. Volume636,204
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)9.06
Price to Sales (P/S)4.69
P/FCF Ratio-25.60
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue6.85
Enterprise Value/Gross Profit11.37
Enterprise Value/Ebitda29.34
Forecast
1Y Price Target
$147.80Price Target Upside3.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Aviation And Logistics CapacityStable and improving TransMedics Aviation flight activity supports the company’s logistics capabilities and recurring service revenue tied to organ transport.
Regulatory Progress And Geographic ExpansionFDA clearance to advance OCS Lung and OCS Heart IDE trials, combined with plans to expand into Europe and pursue OCS Kidney, creates multiple long-term growth pathways.
Transplant Volume GrowthExpanding liver and lung transplant volumes are increasing utilization of the Organ Care System, which should drive higher procedure-related revenue and aftermarket service demand.
Bears Say
Data Revision And Volume RiskRevisions to transplant data and potential slowing in transplant volumes could reduce device utilization and weigh on near-term revenue forecasts.
Limited Near-term Impact From Lung MarketThe lung transplant market is unlikely to contribute meaningfully until the company’s clinical trial progresses, constraining revenue upside from that indication.
Revenue Shortfall ImpactReporting revenue slightly below consensus can prompt investor selling pressure and could push the stock lower despite operational positives.
TransMedics Group News
TMDX FAQ
What was TransMedics Group Inc’s price range in the past 12 months?
TransMedics Group Inc lowest stock price was $55.00 and its highest was $156.00 in the past 12 months.
What is TransMedics Group Inc’s market cap?
TransMedics Group Inc’s market cap is $4.60B.
When is TransMedics Group Inc’s upcoming earnings report date?
TransMedics Group Inc’s upcoming earnings report date is Mar 04, 2026 which is in 49 days.
How were TransMedics Group Inc’s earnings last quarter?
TransMedics Group Inc released its earnings results on Oct 29, 2025. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.361 by $0.299.
Is TransMedics Group Inc overvalued?
According to Wall Street analysts TransMedics Group Inc’s price is currently Undervalued.
Does TransMedics Group Inc pay dividends?
TransMedics Group Inc does not currently pay dividends.
What is TransMedics Group Inc’s EPS estimate?
TransMedics Group Inc’s EPS estimate is 0.39.
How many shares outstanding does TransMedics Group Inc have?
TransMedics Group Inc has 34,174,324 shares outstanding.
What happened to TransMedics Group Inc’s price movement after its last earnings report?
TransMedics Group Inc reported an EPS of $0.66 in its last earnings report, beating expectations of $0.361. Following the earnings report the stock price went up 1.094%.
Which hedge fund is a major shareholder of TransMedics Group Inc?
Currently, no hedge funds are holding shares in TMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TransMedics Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$147.80 (3.57% Upside)
$147.80 (3.57% Upside)
Blogger Sentiment
Bullish
TMDX Sentiment 84%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 89.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $257.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.69%
12-Months-Change
Fundamentals
Return on Equity
32.48%
Trailing 12-Months
Asset Growth
20.43%
Trailing 12-Months
Company Description
TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TMDX Company Deck
TMDX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong year-over-year growth and operational achievements, such as significant revenue growth, improved margins, and international expansion plans. However, there were also challenges including a seasonal slowdown and sequential revenue decline. The overall sentiment is balanced with more highlights than lowlights.View all TMDX earnings summariesTMDX Stock 12 Month Forecast
Average Price Target
$147.80
▲(3.57% Upside)
Technical Analysis
Ownership Overview
3.59% Insiders
41.59% Mutual Funds
0.84% Other Institutional Investors
30.32% Public Companies and Individual Investors